Thomas Scullion PhD’s Post

The oncology landscape is witnessing a transformative era, with innovative companies at the forefront of developing cutting-edge therapies. OS Therapies Inc. is gaining traction for its novel immunotherapy OST-HER2, designed to treat resected, recurrent osteosarcoma. The company's tunable ADC platform, leveraging proprietary SiLinker technology, also holds promise for enhancing the efficacy and safety of antibody-drug conjugates. Actinium Pharmaceuticals, Inc. is developing targeted radiotherapies, with its lead candidate, Iomab-B, nearing potential regulatory submissions for use in bone marrow transplants. Corbus Pharmaceuticals Holdings, Inc. is advancing CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4, showing promising results in metastatic urothelial and cervical cancers. Puma Biotechnology, Inc. has licensed alisertib, an aurora kinase A inhibitor, initially targeting small-cell lung cancer and breast cancer. Recent data on alisertib's use in advanced osimertinib-resistant EGFR-mutated non-small cell lung cancer was presented at the ASCO Annual Meeting, guiding the company's future trial protocol modifications. With innovative pipelines, strategic collaborations, and strong leadership, these companies are well-positioned to capitalize on the expanding oncology market, offering hope for improved patient outcomes. @ostx @atnm @crbp @pumabiotechnology #oncology #biotechnology #immunotherapy #targetedtherapies #cancercare

Discover the Cutting-Edge of ADC Therapies! Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment, combining the precision of monoclonal antibodies with potent cytotoxic agents. Learn about the mechanism, market trends, and the latest analytical techniques driving this innovative field forward. From targeted delivery to improved patient outcomes, ADCs are redefining oncology. https://lnkd.in/gzjekNF6 #ADCTherapies

Radiomer Therapeutics, Inc., a company established by Fannin, is pioneering the development of targeted radiopharmaceuticals and radioligand therapies for theranostic applications. Our innovative approach leverages Fannin's proprietary Raptamer platform which has many unique features such as * Innovative Targeting Vector: Raptamers are based on a single-stranded (ss) DNA backbone with enhanced peptide-like side chains, which improve chemical diversity and increase binding affinity to targets. *Flexible Design: The modular nature of Raptamers allows for the attachment of various linkers, chelators, and isotope payloads, enabling the creation of customized therapeutic agents for specific medical uses. *Targeted Radiopharmaceuticals: High binding affinity allows Raptamers to deliver therapeutic radioisotopes, offering both diagnostic imaging and treatment capabilities. Raptamers deliver radioactive isotopes directly to diseased cells, reducing collateral damage to healthy tissues. By harnessing the unique properties of Raptamers, Radiomer Therapeutics aims to revolutionize personalized medicine and targeted therapy, addressing critical needs in diagnosing and treating various diseases. For more details: Please see the attached press release.

ENHERTU, a groundbreaking ADC for HER2 positive cancers, wins the 2024 Prix Galien USA Award, spotlighting the power of innovation and collaboration between Daiichi Sankyo and AstraZeneca in transforming cancer treatment. 🌟 #RegulatoryAgencies #Pharma #BiotechExcellence #CancerInnovation #PharmaceuticalCompanies #MarketAccessToday #MarketAccess

Are you headed to #ESMO2024 this week?! Check out this preview that dives into the groundbreaking advancements in oncology, spotlighting bispecifics and TIGITs as some of the hottest topics. . Do you agree that these innovative therapies are poised to redefine cancer treatment and bring new hope to patients worldwide?! . #Oncology #CancerResearch #Biologics #InnovationInMedicine #MedicalAffairs

This "Ask the Experts" feature delves into the pressing inquiries regarding the application of patient-derived organoid technology in cancer research. Dr. Robert Vries, our CEO, extensively discusses the implications of the FDA Modernization Act 2.0, the integration of organoids in the development of oncology drugs, and our notable scientific advancements in refining our service offerings for oncology and immuno-oncology drug development. Click on the link to read the article. #organoids #cancer #oncologyresearch #tumororganoids

Angle announces study of ovarian cancer CTCs using Parsortix system

TerraPower #Isotopes first commercial-scale producer of #actinium225 - in trials for #ProstateCancer Treatment 1. Actinium-225 (225Ac) Emergence in Prostate Cancer Therapy:   - 225Ac has become a promising alpha-emitting radionuclide for targeted alpha therapy (TAT) in prostate cancer.   - It offers high linear energy transfer (LET) and a short path length, potentially improving efficacy in micrometastatic disease. 2. Commercial Production Milestone:   - TerraPower Isotopes began commercial-scale production of 225Ac on October 1, 2024.   - This development provides weekly access to pharmaceutical companies globally, addressing previous supply limitations. The commercial production of 225Ac represents a significant milestone in the field of targeted alpha therapy for prostate cancer. It addresses a critical supply bottleneck, potentially accelerating the clinical development and broader application of these promising therapies. While challenges remain, particularly in managing side effects and optimizing delivery, the increased availability of 225Ac is likely to drive rapid advancements in the treatment of advanced prostate cancer, especially for patients with limited therapeutic options.

Indapta Therapeutics announced it has closed a $22.5M round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer cell therapy. The funding will support the generation of substantial additional data from Indapta's ongoing trial of IDP-023 in cancer and provide initial data from the first trial in autoimmune disease. Read more: https://buff.ly/4gn163K #LifeScienceWashington #IndaptaTherapeutics #CellTherapy

Angle announces study of ovarian cancer CTCs using Parsortix system